Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia
Zanfina Ademi, Kumar Pasupathi, Danny Liew
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | SAGE PUBLICATIONS LTD | Published : 2015
OBJECTIVE: To determine the cost-effectiveness of apixaban versus warfarin in patients with atrial fibrillation (AF) with a moderate to severe risk of stroke, from an Australian government-perspective. METHODS: A decision-analytic Markov model was constructed to assess the cost-effectiveness of apixaban versus warfarin, based on data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF (ARISTOTLE) trial. The model comprised five health states: 'Alive, no major bleeding or stroke', 'Alive, no major bleeding, post stroke/systemic embolism', 'Alive, post major bleeding, no stroke', 'Alive, post-major bleeding and stroke' and 'Dead'. Disease cost data was derived from ..View full abstract
Kumar Pasupathi has received research grants from pfizer Australia. Danny Liew has received honoraria and research grants from pfizer Australia.